ALK and non-small cell lung carcinoma: Despite the small number of cases, their results indicated that the early reduction in the FDG uptake in the tumor mass after initiation of molecular agents could predict the subsequent tumor response in patients with EGFR-mutated or ALK-rearranged NSCLC [27].